1.89
-0.15 (-7.35%)
| Previous Close | 2.04 |
| Open | 2.02 |
| Volume | 1,382,001 |
| Avg. Volume (3M) | 1,116,698 |
| Market Cap | 570,892,672 |
| Price / Sales | 283.41 |
| Price / Book | 97.15 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2026 |
| Operating Margin (TTM) | -17,994.78% |
| Diluted EPS (TTM) | -0.590 |
| Total Debt/Equity (MRQ) | 0.91% |
| Current Ratio (MRQ) | 10.96 |
| Operating Cash Flow (TTM) | -121.30 M |
| Levered Free Cash Flow (TTM) | -114.20 M |
| Return on Assets (TTM) | -28.29% |
| Return on Equity (TTM) | -45.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ProKidney Corp. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 30.05% |
| % Held by Institutions | 42.03% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Artia Global Partners Lp | 31 Mar 2026 | 1,806,939 |
| Brown University | 31 Mar 2026 | 1,000,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |